Objective. Low-dose local anesthetic is often used in cervical interlaminar epidural steroid injections (CIESI), yet its effect on upper extremity strength has not been studied. The presence of consequent weakness has potential implications for postprocedure safety. This study aimed to determine whether low-dose lidocaine in a C7-T1 CIESI causes objective weakness.
Introduction
Cervical radicular pain is a common problem that is often treated by epidural steroid injection [1] . While clinical practice guidelines do not specifically recommend or discourage the use of local anesthetic in the epidural V C 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com injectate [2] , the majority of the published literature on clinical outcomes of cervical epidural steroid injection includes the use of lidocaine in the epidural injectate [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Consequently, many practitioners elect to use local anesthetic in the epidural injectate in order to obtain additional diagnostic information when the precise source of pain is not clear from clinical presentation and imaging. Local anesthetic may also be included in order to provide immediate pain relief in cases of exquisitely painful acute radicular symptoms.
Local anesthetic injection into the epidural space has the potential to cause weakness of the extremities. High-dose local anesthetic in the cervical epidural space [13] and inappropriately placed low-dose local anesthetic in the subdural space or subarachnoid space [14, 15] are known to cause motor weakness. Appropriately placed, low-dose local anesthetic injected into the epidural space via a transforaminal approach, in close proximity to the exiting spinal nerve root, causes motor block in a small proportion of patients [16] . However, the effect of low-dose injection of local anesthetic in the cervical interlaminar epidural space on objective upper extremity strength has not been characterized in the published literature. This proposition affects postprocedure instructions as even mild weakness may pose a hazard during the performance of manual activities that require the upper extremity/ extremities such as using a handrail or cane handle for support. The present study aimed to determine whether a standard dose of 1 mL 1% lidocaine included in a C7-T1 cervical interlaminar epidural steroid injection (CIESI) causes an objective change in strength as measured by dynamometry. We hypothesized that cervical epidural lidocaine would cause an objective decrease in strength in functional movements of the upper extremity controlled by the cervical myotome(s) closest to the site of lidocaine injection.
Methods

Study Design
This was a prospective case series conducted at an academic pain center. The study was approved by an institutional review board (STU00089080). All patients provided written informed consent.
Participants who were part of a different clinical outcome study that included only unilateral C2-C6 radicular pain [11] were offered participation in the present study. All participants signed a written informed consent form for study participation.
Patients were enrolled in the study between April 2014 and August 2014. Criteria for study inclusion were diagnosis of unilateral cervical radicular pain, magnetic resonance imaging (MRI) pathology consistent with clinical symptoms/signs, numerical rating scale (NRS) pain score of 4 or higher, pain duration four or more weeks, and failed trial of conservative therapy (medications, physical therapy, or chiropractic care). Exclusion criteria included refusal to participate, refusal to provide consent, or contraindications to CIESI (active infection, bleeding disorders, current anticoagulant or antiplatelet medication use, allergy to medications used for CIESI, pregnancy), cervical spinal cord lesions, cerebrovascular, demyelinating or other neuromuscular disease, current glucocorticoid use or ESI within past six months, prior cervical spine surgery, or patient request for or requirement of conscious sedation during the injection procedure.
Procedures
All procedures were performed at a single facility. Proceduralists were faculty, board certified in anesthesiology, with additional subspecialty certification in pain medicine. A total of three attending physicians performed the procedures. Trainees in an Accreditation Council for Graduate Medical Education-accredited Multidisciplinary Pain Medicine fellowship participated in the procedures in 91% of cases; an attending physician supervised and/or personally performed all injections.
Participants were positioned prone on a fluoroscopy table, and an non-invasive blood pressure (NIBP) monitor and pulse oximeter were placed. The cervical spine region was prepped with chlorhexidine and draped in a sterile manner. No participants received procedural sedation of any nature. Fluoroscopy was used to identify the C7-T1 interspace in all procedures. After injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 17G 3.5 inch Tuohy needle was placed at the C7-T1 level and a loss of resistance (saline) technique was used to gain access to the epidural space; needle position was confirmed in anterior-posterior and lateral views. Once a satisfactory target position was achieved, 0.5 to 1 mL of contrast (Omnipaque-180, GE Healthcare, Princeton, NJ, USA) was injected under live fluoroscopic observation. Upon confirmation of a satisfactory epidural contrast pattern, the injectate was delivered, which consisted of 2 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of 1% preservative-free lidocaine.
Data Collection
Prior to injection, baseline demographic, clinical, and imaging information were collected: age, gender, body mass index (BMI), duration of symptoms, spinal root level affected, side of symptoms, and concordant MRI findings.
Strength Measurement
Bilateral upper extremity strength testing was performed in all patients immediately prior to CILESI, as well as at 15 minutes and 30 minutes following CILESI. A single trained research assistant performed all measurements to reduce measurement bias. Elbow flexion (EF; C5 myotome), wrist extension (WE; C6 myotome), elbow extension (EE; C7 myotome), and handgrip (C8 and T1 Strength with Low-Dose Cervical Epidural Lidocaine myotomes) strength were assessed using a calibrated, digital handheld dynamometer (Push-Pull Dynamometer, Fabrication Enterprises Inc., White Plains, NY, USA). A calibrated digital handgrip dynamometer (Jamar Plus Digital Hand Dynamometer, Patterson Medical, Warrenville, IL, USA) was used to assess handgrip strength. A standard protocol was used to isolate each joint movement and force production, as well as grip strength, as previously described [17, 18] , and participants were coached to provide maximum effort with each maneuver. Strength measurement of each action was performed and recorded three times, and the highest value was recorded. Validation studies using similar protocols for upper extremity functional strength measurement show a high degree of test-retest reliability with a narrow range of variability [19] [20] [21] [22] [23] .
Follow-up
Participants were contacted by telephone two weeks following injection. At this time, a standard questionnaire was administered that included a query regarding any ongoing subjective weakness since the time of injection as well as any adverse events or complications experienced following the CIESI procedure.
Data Analysis
Strength data was evaluated both as the raw values (kg) and using a categorical responder analysis. For the responder analysis, changes in dynamometry values between baseline and 15 minutes and baseline and 30 minutes following CIESI were classified as 1) increased, 2) 0% to 19.9% decreased, or 3) 20% or greater decreased for both the left and right upper extremity. The categorical threshold of a 20% or greater decrease in myotomal strength was selected as a 19.5% decrease in handgrip strength, as measured by dynamometry, which has been demonstrated as the minimum threshold for self-perception of weakness [24] .
Statistical Analysis
Raw strength measurements in each dermatome were compared using a generalized linear model with side (right or left) and time (baseline, 15 minutes, and 30 minutes) as repeated measures. Tests of within-subject contrasts were calculated between 15 minutes and baseline and 30 minutes and baseline. A P value of less than 0.05 was required to reject the null hypothesis. Correlations between change in strength from baseline and the change in pain score from postinjection from pre-injection were determined using Spearman's rho. For the responder analysis, the proportion of patients and 95% confidence intervals (CIs) of the proportions for subjects that met the threshold of a 20% or greater decrease in myotomal strength were calculated using the method of Wilson. The proportion was considered significant if the 95% CI of the proportion of patients did not include zero at the tested myotomal level. 
Results
Baseline demographic, clinical, imaging, and characteristics, as well as baseline strength data, are shown in Table 1 . The study sample included 27 participants, with a greater proportion of females (N ¼ 17, 59%). Radicular symptoms at the C6 level were most common (N ¼ 20, 69%). Foraminal stenosis (N ¼ 12, 45%) followed by disc/disc-osteophyte complex protrusion (N ¼ 8, 28%) were the most common primary concordant etiological findings on MRI.
Strength assessments for each myotome are shown in Figures 1 through 4 . The percentage change in myotomal strength relative to baseline is shown for each individual participant at the 15-minute and 30-minute intervals in Table 2 . At both 15 minutes and 30 minutes postinjection, there was no within-participant difference in median EF, WE, EE, and handgrip strength from baseline bilaterally (all Ps > 0.05). There was no correlation between strength changes and either postprocedure pain scores or the change in postprocedure pain score from baseline (all Ps > 0.05).
Results of the categorical analysis are shown in Tables  3 and 4 . At 30 minutes postinjection, five of 27 unique participants (19%, 95% CI ¼ 4-33%) demonstrated a 20% or greater decrease in strength in at least one myotomal distribution. Stratified by myotome, a 20% or greater decrease in strength was present in left EF 4% (95% CI ¼ 0-11%), right EF 7% (95% CI ¼ 0-17%), left WE 4% (95% CI ¼ 0-11%), and right WE 7% (95% CI ¼ 0-17%).
No participant reported subjective upper extremity weakness at two-week follow-up, and there were no serious procedure-related adverse events. Two participants experienced transient vasovagal reactions that did not require procedure termination; symptoms resolved within less than five minutes postprocedure (10 minutes prior to strength retesting by dynamometry). These two participants did not demonstrate a 20% or greater decrease in strength in any myotome tested.
Discussion
In this prospective case series, we observed no overall evidence of objective upper extremity weakness within 30 minutes of a standard image-guided C7-T1 CIESI when only 1 mL 1% lidocaine was used in a 3 mL injectate. However, categorical responder analysis revealed that 19% (95% CI ¼ 4-33%) of participants experienced a 20% or greater reduction in strength in at least one myotomal distribution, with the 95% CI notably not crossing zero, indicating a proportion that is statistically significantly greater than zero.
A decrease in strength from baseline was detected primarily in the C5 and C6 myotome distributions, which was contrary to our hypothesis that weakness would be demonstrated in the functional movements facilitated by the myotome(s) closest to the level of epidural access (C7/C8/T1). Given that all participants in this study sample had either C5 or C6 radicular pathology, it may be that affected nerve roots are more susceptible to a partial motor block even from low-dose lidocaine. This 
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finding is also consistent with evidence that CIESI with needle entry at the C7-T1 level and an injectate volume of only 2.5 mL reaches the C4 level in 60% of patients [10] . While the effects of differing concentrations of medication at levels cranial to the point of entry for CIESI have not been studied, the present study confirms that a proportion of patients who receive low-dose epidural lidocaine may experience weakness as far cranial as the C5 myotome.
Interestingly, while weakness was demonstrated, a large proportion of participants also experienced increased strength represented in all myotomes tested (C5-T1).
The effects of pain inhibition on extremity and core strength are well established [25] [26] [27] . In the present study, it is feasible that the anesthetic effect of lidocaine removed such pain inhibition, which was reflected as increased strength upon dynamometric measurement in some myotomes.
These findings have implications for patient safety following CIESI in the ambulatory setting. A previous study found that the minimum change in handgrip strength that is perceptible to a patient, as measured by dynamometry, is 19.5% [23] . Nineteen percent of participants in the present study demonstrated a 20% or greater reduction in strength in at least one myotomal distribution. Thus, while is it unknown what degree of weakness is necessary to affect upper tasks such as handrail support or use of a cane, the present findings encourage clinicians to modify postprocedure instructions and precautions as elevated fall risk is a possibility in a proportion of individuals who receive even low-dose lidocaine in the cervical epidural space. This consideration is particularly salient for patients with poor baseline strength, vision, balance, or any comorbid neuromuscular condition that increases risk of falls.
Based on these findings, we recommend that physicians and/or staff counsel patients regarding the realistic chance of temporary postprocedure weakness even when injectate deposition is ideal (i.e., epidural with no subdural, intrathecal, or vascular trespass), and a longer period of postprocedure observation should be considered. It is likely that the objective decreases in strength resolved following the typical time range of the duration of action of lidocaine (one to two hours) [28] , but future study will be needed to confirm this. Furthermore, if higher concentrations or volumes of lidocaine are used, a greater frequency and magnitude of weakness may be expected following CIESI. Practitioners should err on the side of caution, especially in the litigious milieu in which physicians now practice. This new data also provides information from which to weigh the potential benefits against the risks of using local anesthetic in the cervical epidural space in the conduct of these commonly performed procedures, particularly given the known risks of lidocaine inappropriately injected to the subdural or subarachnoid space [29] .
This study must be interpreted within the context of its limitations. Objective strength measurements were not made past 30 minutes. We did not design the study to include a comparative group that used only saline rather than lidocaine. We did not perform an internal validity study to determine how much normal variation in measurement exists with the specific strength assessment protocol in this study. However, validation studies using similar protocols for upper extremity functional strength measurement show a high degree of test-retest reliability with a narrow range of variability [19] [20] [21] [22] [23] . For example, one study showed a standard error of measurement of 1.2 kg for elbow flexion as measured by handheld dynamometry [23] . If applied to the present study sample, this would represent a 4.8% standard error of measurement given a median EF force output of 25 kg. The study sample was small; however, the frequency of clinically significant weakness was of a robust frequency to demonstrate statistical significance, and the sample represents a realistic clinical population that supports the generalizability of the present findings. Because of the limited number of participants, we did not perform subgroup analyses that could identify predictive factors for postprocedure weakness. A larger study with objective strength measurement by dynamometry with measures taken at longer time intervals following injection with internal validation to determine test-retest reliability may be useful in further defining the duration, accuracy, and predictive factors of the effects observed in the present study.
Conclusions
The present data suggest that CIESI with an injectate volume of 3 mL that includes 1 mL of 1% lidocaine may result in objective upper extremity weakness that is above the minimum subjective threshold in a subset of patients. Further study should include a control group and internal validation to confirm the present results.
